The abstract is read at the publisher; the summary is JClub's.
AASLD/AGA guideline for adults with primary biliary cholangitis agrees on six evidence-based recommendations, including UDCA first-line therapy and linerixibat for moderate-to-severe pruritus.
- Why it matters: PBC remains linked to progressive fibrosis, cirrhosis, transplantation, and premature mortality, with ongoing gaps in diagnosing antimitochondrial antibody-negative disease, judging UDCA response, and managing pruritus and post-transplant recurrence.
- What they did: An AGA/AASLD multidisciplinary panel used systematic reviews for six prioritized clinical questions, applying GRADE and an Evidence to Decision Framework to craft recommendations for adults with PBC.
- The result: The panel’s recommendations cover PBC-specific antinuclear antibodies in antimitochondrial antibody-negative suspected PBC, liver stiffness for prognostication, PPAR agonists after inadequate UDCA response or intolerance, linerixibat for moderate-to-severe pruritus, and UDCA prophylaxis after transplantation, with evidence certainty from moderate to very low.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.